Akorn Extends Lenders Standstill With Aim To Sell Company
Fourth Quarter Losses Narrow But Figures Miss Analyst Targets
US generics company Akorn, which has been struggling since Germany’s Fresenius walked away from a $4.3bn merger three years ago, plans to put itself up for sale under an extended standstill agreement with lenders.
